Drug Profile
Enmetazobactam - Allecra Therapeutics
Alternative Names: AAI-101; OCID‐5090Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Orchid Chemicals & Pharmaceuticals
- Developer Allecra Therapeutics
- Class Antibacterials; Penicillins; Small molecules; Sulfones; Triazoles
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in USA (IV)
- 24 Jun 2020 Interim pharmacokinetics data from a phase I trial in Gram negative infections released by Allecra Therapeutics
- 31 Jan 2019 Allecra completes a phase I trial in Gram-negative infections (In volunteers) in USA (IV) (NCT03775668)